UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the
month of July 2026

 

Commission
File Number 001-15170

 

 

GSK plc

(Translation
of registrant’s name into English)

 

 

79 New Oxford Street, London, WC1A 1DG

(Address
of principal executive office)

 

 

 

Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

 

Form
20-F . . . .X. . . . Form 40-F . . . . . . . .

 

 

Issued: 24 July 2026, London UK

 

Admission to trading

 

 

In conformity with PRM 1.6.4R, GSK plc notifies the market
that ordinary shares of 31¼ pence each (‘Ordinary Shares’)
have been admitted to trading as set out in the table below. The
Ordinary Shares have been admitted to trading under existing block
listing admissions of Ordinary Shares in connection with the
“GlaxoSmithKline plc Share Save Plan 2022”.

 

1a

Issuer
name

 

GSK
plc

1b

Issuer
LEI

 

5493000HZTVUYLO1D793

2

Regulated
market on which the securities have been admitted to
trading

 

London
Stock Exchange – Main Market

3

Name,
type and ISIN of the securities

Ordinary
Shares of 31¼ pence each

 

ISIN:
GB00BN7SWP63

 

4

Number
of further securities admitted to trading covered by this
notification

 

70,759

5

Total
number of securities admitted to trading following
admission

 

4,316,292,310

6

Fungibility

 

Fully
fungible with existing Ordinary Shares

7

Date
range covered by the notification

29
May 2026 – 24 July 2026

 

8

Prospectus
information

N/A

 

 

 

V A Whyte

Company Secretary

 

24 July 2026

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.

 

 

Registered in England & Wales:

 

No.
3888792

 

 

Registered Office:

 

79
New Oxford Street

 

London

 

WC1A 1DG

 

 

 

 

SIGNATURES

 

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.

 

GSK plc

 

(Registrant)

 

 

Date: July
24, 2026

 

 

 

 

By:/s/ VICTORIA
WHYTE

————————–

 

 

 

Victoria Whyte

 

Authorised
Signatory for and on

 

behalf
of GSK plc